Document:

Exhibit 10.12

 

Agreement

 

Entered into in Jerusalem on June 1,
2009

 

Between 

 

Intec Pharma Ltd.

P.C. 513022780

of 12 Hartom St., Jerusalem, PO
Box 45219

(the “Company”)

of the first part;

 

And between

 

Zeev Weiss, I.D. 057245581

of 27/17 Hamitzpe St., Shoham, PO Box 2785

(“Zeev”)

of the second part;

 

		Whereas	the Company engages in the field of drug enhancement;
and

 

		Whereas	the Company approached Zeev in order to continue to receive professional services from Zeev, in
the framework of which he acts as deputy CEO of the Company, and Zeev granted the request and wishes to continue to act as deputy
CEO of the Company, all as defined in this Agreement; and

 

		Whereas	Zeev has provided professional services and acted as deputy CEO since September 20, 2006;

 

Wherefore, the Parties have agreed,
represented and stipulated as follows:

 

		1.	Preamble, Annexes and Section Headings

 

		1.1.	The preamble to this Agreement and the annexes hereto constitute an integral part hereof and the
Parties undertake and are engaging according thereto.

 

		1.2.	The section headings are for convenience purposes only and shall not be used for interpretation
of this Agreement.

 

		2.	Term of the Agreement

 

This Agreement is for a period
of 36 months from September 20, 2008 [the date of expiration of the previous agreement]. Each party will be entitled to terminate
this Agreement at any time by written notice to the other party of 60 days.

 

		3.	Nature and Scope of the Position

 

Zeev will act as deputy CEO and
as an officer of the Company and will be responsible for the business aspects of the Company, such as the Company’s business
model, its business strategy, examination and consummation of additional business avenues to increase the Company’s value,
business development and cooperation with other companies, raising capital for the Company, receipt of government incentives in
Israel and worldwide etc. Zeev shall report directly to the Company’s CEO.

 

    	 

    	 

    

  

It is clarified that Zeev will
have other occupations, in the field of life sciences and in other fields, over and above his activity at the Company, and the
estimated scope of his activity with the Company will be approx. 90 monthly hours. In the event that the scope of his activity
will be different, the consideration due to him as specified in this Agreement will be changed accordingly. Zeev will deliver to
the Company, each month, a specification of the number of hours he engaged in the Company’s affairs.

 

		4.	Zeev’s Representations and Undertakings

 

Zeev represents and undertakes
that:

 

		4.1.	He has the knowledge, ability, experience, skills and proficiency required for the purpose of performance
of his duties.

 

		4.2.	There is no legal and/or contractual impediment to his engagement in this Agreement, to fulfilment
of his undertakings or fulfillment of the position assigned to him according to this Agreement.

 

		4.3.	He has not been indicted for and/or convicted of any criminal offense, including an offense involving
moral turpitude, no criminal case has ever been opened against him at the Israel Police, and to the best of his knowledge no investigation
is currently being conducted against him.

 

		4.4.	Perform his duties honestly, with dedication, loyalty and proficiency and use his best efforts
to promote the Company.

 

		4.5.	In the framework of his position he will work under the CEO and the board of directors of the Company,
and will comply with their instructions in relation to his work and/or his position, including but without derogating, instructions
and/or directions in relation to work procedures, performance of resolutions of the Company’s board of directors, and any
other instruction of the CEO and board of directors of the Company.

 

		4.6.	He will not commit on the Company’s behalf and will not use its name, over and above the
authorities conferred on him according to this Agreement and/or authorities that shall be explicitly defined by the Company’s
management.

 

		4.7.	He will keep confidential all of the terms and details of this Agreement, unless required \pursuant
to any law.

 

		5.	Insurance and Indemnification

 

The Company’s officers’
policy shall be extended to include and cover Zeev’s activity in connection with the Company, and Zeev will be granted indemnification
in respect of his activity as aforesaid at the accepted scope for officers of the Company.

 

    	2

    	 

    

  

		6.	The consideration and the manner of payment thereof

 

		6.1.	In consideration for 90 monthly hours that he shall dedicate to the Company’s business according
to this Agreement, the Company shall pay Zeev NIS 30,000 (thirty thousand) per month, plus V.A.T as required by law (the “Consideration”).

 

		6.2.	The Consideration shall be paid to Zeev by the Company once a month, in respect of the previous
month, within 7 days from the date of receipt of a lawful tax invoice that shall be delivered to the Company’s offices within
7 days from the end of the month for which the payment is requested. The Company shall withhold at source funds as required by
law, unless an exemption from withholding at source is presented thereto.

 

		6.3.	The Company shall provide Zeev with a Ford Focus or similar car and shall bear all of the fixed
and variable maintenance expenses, including licenses, insurance, fuel, repairs etc. The car shall remain the Company’s property,
and shall be returned thereto by Zeev upon expiration of the Agreement.

 

		6.4.	In the framework of overseas travel on behalf of and for the Company, Zeev will be entitled to
flight expenses and accommodation overseas, which shall be covered and paid by the Company. The Company shall take out an insurance
policy and medical insurance for Zeev for the period of his overseas travel.

 

		6.5.	The Company shall provide Zeev with a mobile phone and pay him reimbursement of expenses in the
sum of NIS 400 per month for calls on the mobile phone.

 

		6.6.	If the scope of Zeev’s activity shall exceed 90 monthly hours, he will be entitled to additional
consideration of NIS 290 (plus V.A.T as required by law) per hour, although the additional charge will be made in respect of units
of 10 hours actually worked and less than 10 hours’ work will not entitle him to additional consideration (i.e. if Zeev works
98 hours he will not receive an increment and if he works 105 hours he will receive an increment only for 10 hours etc.).

 

		6.7.	In addition to the aforesaid, Zeev will be entitled to bonuses and options as specified in Annexes
A and B to this Agreement.

 

		6.8.	It is clarified that lawful V.A.T, insofar as applicable, shall be added to any payment to Zeev
according to this Agreement and the annexes hereto.

 

		6.9.	This Agreement absolutely determines the relationship between the Parties, their mutual obligations
and rights. Zeev will not be entitled to any payment and/or right and/or benefit from the Company that is not explicitly mentioned
in this Agreement.

 

		6.10.	Commencing from the execution of this Agreement, there neither is nor will be any employment relationship
between Zeev and the Company. The Company shall not owe Zeev in respect of provision of the services any liability owed by an employer
to an employee, and Zeev shall be deemed as an independent contractor for all intents and purposes.

 

    	3

    	 

    

  

		6.11.	For the avoidance of doubt, it is clarified that any and all mandatory payments, including payments
of income tax and national insurance in respect of services that have been and shall be provided by Zeev will be paid directly
by Zeev and it is he who bears personal and sole liability for payment thereof.

 

		6.12.	If, despite the Parties’ declared intentions, it is determined that an employment relationship
exists between the Company and Zeev, the Parties agree that in lieu of the Consideration stated in Section 6.1 above, the Company
shall owe Zeev 65% of the sum of the Consideration stated in Section 6.1 above.

 

		6.13.	Zeev shall compensate and/or indemnify the Company for any expense and/or damage and/or payment
that the Company shall incur due to non-fulfillment of one or more of his undertakings in Section 6.10, including legal expenses
that the Company shall bear, and Zeev agrees in advance that any claim of his which contradicts this document shall be summarily
dismissed with and/or without prejudice.

 

		7.	Confidentiality

 

Without derogating from Annex
B, the confidentiality undertaking attached hereto as an integral part hereof, during the term of the agreement and for 4 years
thereafter, Zeev undertakes to keep confidential any confidential information that shall reach him from the Company, not to transfer
or make use of information that is in his possession and which relates, directly and/or indirectly, to the Company’s business,
to its list of customers, the scope and/or nature of its business activity, and not to deliver such information other than to anyone
who the Company shall have determined is authorized to receive the same.

 

Zeev further undertakes to keep
fully confidential and not to disclose, reveal or deliver, whether during or after the term of the Agreement, to any person or
body, secrets pertaining to know-how and/or information relating to the services and/or engagements made between the Company and/or
between Zeev and between any one of them and any third party, other than to anyone who the Company shall have determined is authorized
to receive the same.

 

		8.	Intellectual property

 

Without derogating from Annex
B, attached hereto, any privileged information, including any creation, concept, invention, improvement, idea, process, know-how,
conclusions, copyright, patent, invention, refinement, design, development and any other intellectual property right etc. –
that is developed or invented by Zeev, alone or together with others, during or in connection with his work at the Company, will
be the sole property of the Company, and Zeev will have no right to ownership and/or royalties and/or consideration and/or any
other right in connection with such information.

 

The provisions of this section
shall survive the end of the term of this Agreement, for whatever reason, or termination hereof, indefinitely.

 

    	4

    	 

    

  

		9.	General

 

		9.1.	It is represented that this Agreement and the annexes hereto include everything that has been agreed
between the Parties. Any modification of this Agreement and the annexes hereto shall be made in writing and signed by both Parties
only. No modification otherwise made shall be valid.

 

		9.2.	Failure to exercise a right according to this Agreement shall not be deemed as a waiver thereof.

 

		9.3.	The Parties’ addresses for purposes of this Agreement are as specified in the preamble to
this Agreement. Any notice that is sent by registered mail by one party to the other shall be deemed as having been delivered to
its destination 72 hours after dispatch thereof from the post office, and if hand delivered, upon delivery thereof.

 

In witness whereof, the Parties have
hereto set their hands

 

	/s/ Giora Carni	 	/s/ Zeev Weiss
	Intec Pharma Ltd	 	Zeev Weiss

 

    	5

    	 

    

 

Annex A

 

	1.	a.	 On the date that the Agreement takes effect, Zeev
shall be allotted 5232 options of the Company (which reflect 1.875% of the Company’s shares on a fully diluted basis –
i.e. 1.875% of the sum total of the shares, securities convertible into shares, undertakings and options allotted by the Company
assuming that they will all be converted). [According to a key of 0.625% options per year – the same as the agreement that
was in effect until September 2008, according to 3 years, the previous agreement being for two years]. 1162 options will be exercisable
from June 1, 2009.

 

		b.	In addition to the aforesaid, Zeev will be allotted,
on a one-time basis, on the date on which the Agreement takes effect, 5580 options of the Company (which reflect 2% of the Company’s
shares on a fully diluted basis – i.e. 2% of the sum total of the shares, securities convertible into shares, undertakings
and options allotted by the Company assuming that they will all be converted). The said options will fully vest only if a material
agreement is signed between the Company and a third party, if the date of execution of the material agreement is during the term
of this Agreement and if it is signed in the period of up to 12 months after expiration of the term of this Agreement.

 

			If no material agreement is signed between the Company and a third party as aforesaid in the term
of the Agreement or within 12 months after expiration thereof, all of the options allotted according to Section 1.b shall expire
and be deemed null and void.

 

			The exercise of the options allotted to Zeev according to Section 1.b is contingent upon Zeev working
at a scope of approx. 90 hours per month on average and more during the term of the Agreement, although it is clarified that this
restriction shall not apply in the 12-month period after expiration of the Agreement.

 

		2.	The options mentioned in Section 1.a above which cannot be exercised immediately (4070) will be
exercisable in 8 equal quarterly installments. The first installment will be exercisable on September 1, 2009, and will subsequently
be exercisable once every 3 months (in this section: “Quarter”), provided that Zeev will be employed by the
Company. In the event of termination of Zeev’s activity in the course of a certain Quarter (one of the three-month periods
as aforesaid), he will be entitled to exercise the next installment as if he worked at the Company until the end of the Quarter
during which the prior notice period ended.

 

		3.	Without derogating from the aforesaid, all of the options that shall be allotted to Zeev according
to this Agreement will be subject to the following conditions:

 

		3.1.	The exercise price for receipt of a share will be NIS 0.01. The vesting of the options (Zeev’s
entitlement to exercise options) will be as specified in this annex.

 

    	6

    	 

    

  

		3.2.	In cases in which the Company (in this annex the term company includes a subsidiary of the Company
and/or an affiliate of the Company) is issued and/or sold and/or control of the Company is transferred and/or a majority of its
assets are sold and/or the Company’s business is merged with another company (including a “reverse acquisition”
in which the Company’s shareholders will hold the majority of the shares of the merged company) and/or the Company’s
business or part thereof is transferred to a subsidiary or sister company (spin off) and/or a license is granted for all or a majority
of the Company’s assets – Zeev’s right to exercise the options will be accelerated and he will be entitled to
exercise all of the options allotted to him immediately, even if their exercise date as stated in Section 2 above shall not yet
have arrived.

 

		3.3.	The options will be allotted in the framework of an option plan on a capital track which meets
the requirements of Section 102 of the Income Tax Ordinance on a trustee track.

 

		4.	The entire section is revoked.

 

		5.	The entire section is revoked.

 

		6.	The entire section is revoked.

 

		7.	The Company shall consider granting a bonus of up to 3 monthly payments a year to Zeev (in accordance
with the average payments made to him during the period until the decision) in view of excellent performance, meeting assignments
which can create material value for the Company such as development of new applications for the technology. In any event, the same
will be subject to the sole discretion of the Company’s competent organs, during the term of the Agreement.

 

		8.	It is clarified that with respect to Section 1.b above, “term of the Agreement” means
the period in which Zeev worked at the Company, plus the 60-day period in which any party may terminate the Agreement, while if
the Company asks Zeev not to work in the said 60-day period, or to work at a reduced scope, it shall be assumed for the purpose
of the said sections that he worked the greater of the following two alternatives: (a) the actual scope of the work in the said
60-day period (b) the average that Zeev worked in the three months prior to the giving of the notice.

 

Intec Pharma Ltd. (the “Company”)

 

Personal – confidential

To the addressee only

Date: June 1, 2009

 

Zeev Weiss

I.D. 057245581

 

Dear Zeev,

 

Re: Notice of the allotment / granting
of options

in accordance with Section 102 of
the Income Tax Ordinance (New Version)

 

The board of directors of Intec Pharma
Ltd., P.C. 513022780 (the “Company”) has decided to grant you the right to purchase shares of the Company under
special conditions (“Options”), in accordance with the agreement signed between you and the Company on June
1, 2009 (the “Agreement”).

 

    	7

    	 

    

 

		1.	The main terms and conditions of the Options that it was decided to grant you are specified
below:

 

		1.1.	Number of options: you are hereby granted 10812 options for the purchase of ordinary shares
of the Company.

 

		1.2.	Exercise price: equal in NIS (on the exercise date) to NIS 0.01 per share.

 

		1.3.	Effective date: June 1, 2009

 

		1.4.	Entitlement to exercise the Options: the vesting will be as specified below:

 

From the effective date, 1162 options
may be exercised.

 

From September 1, 2009 –
509 options may be exercised.

 

From December 1, 2009 – 509
options may be exercised.

 

From March 1, 2010 – 509
options may be exercised.

 

From June 1, 2010 – 509 options
may be exercised.

 

From September 1, 2010 –
509 options may be exercised.

 

From December 1, 2010 – 509
options may be exercised.

 

From March 1, 2011 – 509
options may be exercised.

 

From June 1, 2011 – 507 options
may be exercised.

 

5580 options will vest upon the
execution of a material agreement between the Company and a third party, as stated in Section 1.b of Annex A to the Agreement.

 

		1.5.	The tax track – a trustee capital plan pursuant to Section 102.

 

		1.6.	The Company shall notify trustee Guy Bachar – Trust Company and any other body required by
law of the allotment of the Options to you in accordance with the Agreement and the annexes thereto and this letter of grant. The
Company has received all of the approvals required by law, its incorporation documents and its option plan for the purpose of granting
the Options according to the Agreement and this letter.

 

		2.	Manner of exercise:

 

Upon arrival of an exercise date
or acceleration date, you may notify the Company that you wish to exercise a certain number of options (according to your choice,
but no more than the maximum vested quantity). The shares shall be allotted to you within 7 days from the date of provision of
the notice plus the exercise price (NIS 0.01 per share).

 

    	8

    	 

    

 

		3.	Immediate exercise:

 

In any case mentioned in the
option plan or in Section 3.2 of Annex A to the Agreement, all of the exercise dates listed above will be brought forward and the
total quantity of options determined above (plus the adjustments and additions to which you will be entitled) shall immediately
become exercisable (the “Acceleration Date”). In such a case, the options will be exercisable from the Acceleration
Date until 10 years after the effective date. Options not exercised by the end of this period shall expire.

 

		4.	Holding in trust:

 

In order to secure fulfillment
of the tax laws, and to ensure exhaustion of the purchase right proceedings according to the plan, the Options granted to you according
to this letter shall be held in trust by a trustee to be approved for such purpose by the Income Tax Commissioner. In addition,
in the event that you choose not to receive or sell the shares at the time of exercise of the options, these shares will also be
held in the same trust.

 

		5.	Transfer of shares:

 

In the event that you decide
that you wish to sell or transfer the Company’s shares which are received after exercise of the Options to any entity, in
whole or in part, whether for or without consideration, you will be entitled to do so provided that so long as the Company is a
private company, the transfer of the shares is subject to a right of first refusal conferred on the Company’s other shareholders.

 

		6.	Period of the option:

 

The Options may be exercised
until the tenth anniversary of the effective date. Options not exercised by the end of this period shall automatically be
cancelled.

 

		7.	Taxation:

 

Any tax that applies in respect
of the exercise of the Options for shares and/or in respect of the sale thereof shall be borne by you alone, and in the case of
death, heaven forbid, by the heirs, without the Company bearing the same, either directly or indirectly. The applicable tax will
be deducted on the date of the liability from the sale proceeds by the trustee or by the Company, as the case may be. Your (or
your heirs’, in the case of death, heaven forbid) tax liability will be determined pursuant to the provisions of Section
102 of the Income Tax Ordinance and the Income Tax Rules or pursuant to any other law that shall replace them.

 

    	9

    	 

    

 

		8.	Option plan:

 

The Company’s option plan
shall apply to you subject to the changes specified in the Agreement and the annexes thereto and in this letter, and in any case
in which the Agreement and the annexes thereto and/or this letter contain terms that are more favorable to you relative to the
Company’s option plan, the provisions of the Agreement and the annexes thereto or of this letter shall prevail over the provisions
of the Company’s option plan. It is agreed that it will not be possible to prejudice or derogate from your rights or the
rights attached to the Options or the shares for which they shall be exercised without your consent.

 

Sincerely,

/s/ Giora Carni

Intec Pharma Ltd.

 

I hereby agree to the aforesaid:

	/s/ Zeev Weiss	 
	Zeev Weiss	 

 

    	10

    	 

    

 

Translated from Hebrew

 

Amendment to Agreement

Entered into and signed in __________
on _________, 2012

 

		Between:	Intec Pharma Ltd., Private Company 513022780

of 12 Hartom Street,
Jerusalem

(the "Company")

of the
first part;

 

		And:	Ze’ev Weiss, I.D. 057245581

of 27/17 HaMitzpé
Street, P.O.B. 2785 Shoham

("Ze’ev")

of the
second part;

 

		Whereas	Ze’ev serves as the Company’s Deputy CEO under an employment agreement of October 21,
2007 (the “October 2007 Agreement”), which was renewed on June 1, 2009 (the “June 2009 Agreement”;
both agreements, including their annexes, are attached hereto as Annex A and Annex B, respectively);
and

 

		Whereas	the parties intend to amend the June 2009 Agreement.

 

Wherefore the parties have represented,
stipulated and agreed as follows:

 

		1.	The preamble to this amendment to the agreement and the annexes hereto constitute an integral part
hereof.

 

		2.	All of the terms and conditions of the October 2007 Agreement and all of the terms and conditions
of the June 2009 Agreement, including the warrants allotted under such agreements, which shall remain in effect subject to the
terms and conditions of the Company’s option plan, including in the Prior Notice period as hereinafter defined, with the
exception of terms and conditions expressly modified in this amendment to the agreement, shall remain in force and effect.

 

		3.	Section 2 of the June 2009 Agreement shall be deleted and replaced with the following language:

 

“2. Term of the Agreement

 

2.1 This agreement shall become
effective as of April 1, 2011.

 

2.2 Each party may terminate
this agreement at any time and for whatever reason, by prior notice of 180 days, in advance and in writing (the “Prior
Notice”). It is agreed by and between the parties that insofar as Ze’ev is not required by the Company to come
to work during the Prior Notice period, monthly consideration will be paid to him in an amount equal to the average consideration
paid to him during the 6 months preceding the giving of Prior Notice as aforesaid.

 

    	 

    	 

    

 

2.3 Notwithstanding the aforesaid,
it is hereby agreed that the Company may terminate this agreement at any time, Prior Notice not being required and without derogating
from any remedy to which the Company is entitled under any law and/or agreement, upon occurrence of one or more of the following
events:

 

2.3.1 Breach of a fundamental
condition of the conditions hereof.

 

2.3.2 Conviction of a criminal
offence involving moral turpitude.

 

2.3.3 Performance of an act that
constitutes an outright breach of trust against the Company, or an act that knowingly harmed the Company’s reputation”.

 

		4.	In Section 3 of the June 2009 Agreement. “Nature and Scope of Position”, the second
paragraph shall be deleted and replaced with the following language:

 

“It is clarified that Ze’ev
shall have other occupations, in the field of life sciences and other fields, beyond his activity at the Company, but he will dedicate
the majority of his time and energy to his activity at the Company. Ze’ev shall provide the Company with a monthly specification
of the number of hours during which he was engaged in the Company’s affairs”.

 

		5.	Section 6.1 of the June 2009 Agreement shall be deleted and replaced with the following language:

 

“In consideration for the
professional services that Ze’ev shall provide the Company as stated in the June 2009 Agreement, the Company shall pay Ze’ev
NIS 315 for each hour of work up to a monthly cap of 200 hours of work. The aforesaid fee shall be linked to the Consumer Price
index of April 2012 and shall be updated once every calendar quarter”.

 

		6.	Section 6.6 of the June 2009 Agreement shall be deleted.

 

		7.	Section 6.14 shall be added to the June 2009 Agreement in the following language:

 

“6.14.1 Ze’ev shall
be entitled to receive a bonus from the Company, subject to the following conditions:

 

		a.	The Company shall sign a Material Commercialization Agreement with a third party in respect of
one of its products. A “Material Commercialization Agreement” is an agreement, the engagement in which shall
have been lawfully approved by the appropriate organs of the Company under any law, which agreement shall have been defined by
the Company’s board of directors as a material commercialization agreement and which satisfies the following conditions:
(1) an agreement with a company or entity; (2) which enters into an agreement with the Company in connection with the Company’s
core business; (2) the agreement was approved by a majority of votes of the Company’s board of directors; and (4) the agreement
significantly increases the Company’s value.

 

    	2

    	 

    

 

		b.	Ze’ev is employed (including in the Prior Notice period) by the Company on the date of signing
of the Material Commercialization Agreement,

 

		c.	Ze’ev will be entitled to a bonus at the rate of 2% of the consideration actually received
by the Company up to an aggregate amount received by the Company of U.S. $15 million.

 

It is clarified that Ze’ev
shall not be entitled to an additional bonus, in respect of amounts exceeding U.S. $15 million, which are paid, if and insofar
as paid, to the Company.

 

Payment of the tax amount deriving
from receipt of the bonus, insofar a given, shall be fully borne by Ze’ev”.

 

		8.	Section 6.15 shall be added to the June 2009 Agreement in the following language:

 

“6.15 Shortly after the
approval of this addendum and receipt of the approvals required under any law, Ze’ev shall be granted, on a one-time basis,
2,000,000 options for the purchase of 2,000,000 ordinary shares of the Company of par value NIS 0.01 each, against payment of an
exercise price to be determined as the higher of: (a) the average price of the Company’s share on Tel Aviv Stock Exchange
Ltd. (“TASE”) in the thirty trading days preceding the date of approval of the resolution by the audit committee
and the board of directors of the Company (i.e. NIS 0.94); (b) the price of the share on the date of the Company’s initial
public offering on TASE (i.e. NIS 0.952).

 

The grant of such options is
in keeping with the provisions of the Company’s option plan and the annexes thereto. Furthermore, the options shall be allotted
in the name of a trustee in a capital track and shall be subject to the Company’s option plan and the annexes thereto, which
meets the requirements of Section 102 of the Income Tax Ordinance. The aforesaid options shall vest over a 4-year period.

 

The aforesaid options shall vest
in portions, subject to the vesting conditions and within the exercise period as specified below:

 

		1.	1,000,000 options (hereinafter in this section: the “First Portion”) will be
exercisable as of April 1, 2014 (hereinafter in this subsection: the “First Vesting Period”), and until the
end of 72 calendar months as of the granting date thereof. Insofar as the agreement ends after the elapse of the First Vesting
Period, Ze’ev will be entitled to exercise the First Portion in accordance with the provisions of the Company’s option
plan and the annexes thereto.

 

		2.	125,000 options (hereinafter in this section: the “Second Portion”) will be
exercisable as of July 1, 2014 (hereinafter in this subsection: the “Second Vesting Period”), and until the
end of 72 calendar months as of the granting date thereof. Insofar as the agreement ends after the elapse of the Second Vesting
Period, Ze’ev will be entitled to exercise the Second Portion in accordance with the provisions of the Company’s option
plan and the annexes thereto.

 

    	3

    	 

    

 

		3.	125,000 options (hereinafter in this section: the “Third Portion”) will be exercisable
as of October 1, 2014 (hereinafter in this subsection: the “Third Vesting Period”), and until the end of 72
calendar months as of the granting date thereof. Insofar as the agreement ends after the elapse of the Third Vesting Period, Ze’ev
will be entitled to exercise the Third Portion in accordance with the provisions of the Company’s option plan and the annexes
thereto.

 

		4.	125,000 options (hereinafter in this section: the “Fourth Portion”) will be
exercisable as of January 1, 2015 (hereinafter in this subsection: the “Fourth Vesting Period”), and until the
end of 72 calendar months as of the granting date thereof. Insofar as the agreement ends after the elapse of the Fourth Vesting
Period, Ze’ev will be entitled to exercise the Fourth Portion in accordance with the provisions of the Company’s option
plan and the annexes thereto.

 

		5.	125,000 options (hereinafter in this section: the “Fifth Portion”) will be exercisable
as of April 1, 2015 (hereinafter in this subsection: the “Fifth Vesting Period”), and until the end of 72 calendar
months as of the granting date thereof. Insofar as the agreement ends after the elapse of the Fifth Vesting Period, Ze’ev
will be entitled to exercise the Fifth Portion in accordance with the provisions of the Company’s option plan and
the annexes thereto.

 

		6.	125,000 options (hereinafter in this section: the “Sixth Portion”) will be exercisable
as of July 1, 2015 (hereinafter in this subsection: the “Sixth Vesting Period”), and until the end of 72 calendar
months as of the granting date thereof. Insofar as the agreement ends after the elapse of the Sixth Vesting Period, Ze’ev
will be entitled to exercise the Sixth Portion in accordance with the provisions of the Company’s option plan and
the annexes thereto.

 

		7.	125,000 options (hereinafter in this section: the “Seventh Portion”) will be
exercisable as of October 1, 2015 (hereinafter in this subsection: the “Seventh Vesting Period”), and until
the end of 72 calendar months as of the granting date thereof. Insofar as the agreement ends after the elapse of the Seventh
Vesting Period, Ze’ev will be entitled to exercise the Seventh Portion in accordance with the provisions of the
Company’s option plan and the annexes thereto.

 

		8.	125,000 options (hereinafter in this section: the “Eighth Portion”) will be
exercisable as of January 1, 2016 (hereinafter in this subsection: the “Eighth Vesting Period”), and until the
end of 72 calendar months as of the granting date thereof. Insofar as the agreement ends after the elapse of the Eighth Vesting
Period, Ze’ev will be entitled to exercise the Eighth Portion in accordance with the provisions of the Company’s option
plan and the annexes thereto.

 

    	4

    	 

    

 

		9.	125,000 options (hereinafter in this section: the “Ninth Portion”) will be exercisable
as of April 1, 2016 (hereinafter in this subsection: the “Ninth Vesting Period”), and until the end of 72 calendar
months as of the granting date thereof. Insofar as the agreement ends after the elapse of the Ninth Vesting Period, Ze’ev
will be entitled to exercise the Ninth Portion in accordance with the provisions of the Company’s option plans and the annexes
thereto.

 

It is agreed that case, prior
to the end of the vesting period, an event occurs of the sale of all or most of the Company’s securities and/or assets and/or
a public offering of the Company’s securities is made on NASDAQ and/or the Company merges with another Company (hereinafter,
collectively and severally: an “Entitling Event”), the date of establishment of Ze’ev’s entitlement
to exercise all of the options not yet fully vested/matured for ordinary shares, shall be accelerated at the closing date of the
Entitling Event.

 

Payment of the tax amount required
due to the grant of the options and/or the allotment of the shares at exercise of the options, insofar as allotted, shall be fully
borne by Ze’ev”.

 

		9.	In Section 1B of Annex A to the June 2009 Agreement, “in the Prior Notice period” shall
replace “in the period of up to 12 months after the end of the term of this agreement”.

 

		10.	Section 8 of Annex A to the June 2009 Agreement shall be deleted.

 

In witness whereof the parties
have hereunto set their hands

 

	/s/ Zvi
    Joseph and Giora Carni	 	/s/ Ze’ev Weiss
	Intec Pharma Ltd	 	Ze’ev Weiss

 

    	5

    	 

    

  

Translated from Hebrew

 

Addendum to Agreement

Entered into and signed in Jerusalem on November
11, 2013

 

		Between:	Intec Pharma Ltd., Public Company 513022780

of 12 Hartom Street, Jerusalem

(the "Company")

of the first
part;

 

		And:	Ze’ev Weiss, I.D. 057245581

of 27/17 HaMitzpé
Street, P.O.B. 2785 Shoham

("Mr. Weiss")

of the second
part;

 

		Whereas	in January and February 2008 the Company’s board of directors and general meeting of shareholders
approved an agreement with Mr. Weiss dated October 21, 2007, whereby Mr. Weiss provides professional services as of September 20,
2006 and for a period of 24 months as of the date of signing thereof. On June 1, 2009, the services provision agreement with Mr.
Weiss was renewed for a 36-month period commencing on September 20, 2008 (the agreement was updated by the Company’s board
of directors on September 9, 2009). On March 22, 2012 and on March 28, 2012, the Company’s audit committee and board of directors,
respectively, approved the extension of the agreement indefinitely (all shall be hereinafter collectively referred to as the “Original
Agreement”); and

 

		Whereas	on November 11, 2013 the Company’s board of directors approved the appointment of Mr. Weiss
as Co-CEO of the Company; and

 

		Whereas	the parties intend to update the terms and conditions of the Original Agreement, all as specified
in this addendum to the agreement hereinbelow;

 

Wherefore the parties have represented,
stipulated and agreed as follows:

 

		1.	The preamble to this addendum to the agreement and the annexes hereto, if and insofar as attached,
constitute an integral part hereof.

 

		2.	All of the terms and conditions of the Original Agreement, which are in effect as of the date of
the entering into effect of the provisions of this addendum to the agreement (with the exception of terms and conditions expressly
modified in this addendum to the agreement), shall remain in force and effect.

 

		3.	The terms and conditions of the engagement which are contemplated in the addendum:

 

		3.1.	Cash bonus: the cash bonus of U.S. $300,000, which Mr. Weiss would be entitled to under
the provisions of the Original Agreement, shall be cancelled.

 

    	 

    	 

    

 

		3.2.	Options: Mr. Weiss will be allotted, on a one-time basis, 750,000 contingent options for
the purchase of 750,000 Company shares of par value NIS 0.0.1 each, against an exercise price equal to the average of the share’s
closing prices in the 30-day period preceding the board of directors’ resolution on the allotment (the “Contingent
Options”). The Contingent Options shall fully vest and be available for exercise immediately after a Material Agreement
becomes effective. The Contingent Options shall remain in force and effect for a period of up to 72 calendar months as of the granting
date thereof. The Contingent Options shall expire at the end of 90 days as of the date of termination of Mr. Weiss’s employment,
and they shall be deemed null and void and non-exercisable, if, by such time, entitlement to exercise the same shall not have arisen
and the same shall not have been exercised by Mr. Weiss.

 

For this purpose, a “Material
Agreement” shall mean an agreement satisfying the following cumulative conditions: (a) an agreement shall have been signed
with a company or an entity, (b) in a transaction with the Company (or with another entity designated by the Company for the purpose
of such engagement) in connection with the Company’s core business, (c) the agreement shall have been approved by a majority
of the votes of the Company’s board of directors as a material agreement for the Company, and (d) the agreement significantly
increases the Company’s value for a reasonable duration of time.

 

		4.	The provisions of this addendum to the agreement are in effect as of the date of receipt of any
and all approvals required under any law.

 

In witness whereof the parties
have hereunto set their hands

 

	/s/ Giora
    Carni and Nir Sassi	 	/s/ Ze’ev Weiss
	Intec Pharma Ltd	 	Ze’ev Weiss

 

    	2Exhibit 10.13

 

Employment Agreement

 

Entered into and executed in Jerusalem on
November 25, 2013

 

Between

 

Intec Pharma Ltd. Private Company 513022780

of 12 Hartom st. P.O. Box 45219

Jerusalem 91450

 

(the "Company")

 

of the first part                

 

And

 

Name of Employee: Liat Flaishon

I.D.: 022263591

Address: 22 Rosen, Ramat Gan

 

(the "Employee")

 

of the second part                

 

		Whereas	The Employee has expressed his will to be employed by the Company in the office of a VP Business
Development and Medical Affairs (the "Office"), and under the other terms specified in this Agreement below; and

 

		Whereas	The Employee declares that he has the ability, qualifications, credibility and experience required
for the fulfillment of the Office in which he will serve in the Company; and

 

		Whereas	The Employee will be exposed to knowledge and information pertaining to the Company or related
thereto, to the property, business and affairs thereof, the customers thereof, the suppliers thereof, the persons and entities
who have been or are in contact with the Company, including, but without derogating from the generality of the aforesaid –
methods, processes, prices, calculations, human resources management and setting compensation, conditions of agreements in which
the Company is engaged, and other documents of the Company; and

 

		Whereas	The Company and the Employee desire to regulate the terms of employment of the Employee, all as
specified in this Agreement below;

 

Now therefore, it had been declared,
stipulated and agreed between the parties as follows:

 

[signature]

 

    	 

    	 

    

 

		1.	The Substance Agreement

 

		1.1.	This Agreement regulates the relations between the Company and the Employee, and exclusively determines
the terms of engagement of the Employee with the Company.

 

		1.2.	The headings of the clauses in this Agreement are for purposes of the parties' convenience only
and may not be used for interpretation of the Agreement or the terms hereof.

 

		2.	Employee Representations

 

The Employee represents to the Company
as follows:

 

		2.1.	He has the knowledge, ability, experience, qualifications and skills required for the performance
of the Office according to the provisions of this Agreement and the instructions of the Company from time to time.

 

		2.2.	He is not engaged in any other commitment or agreements which prevent him from being bound by this
Agreement, and if that is not the case – he will compensate and indemnify the Company for any expense incurred thereto thereby.

 

		2.3.	He was not indicted nor convicted in any criminal offence, including an infamous crime, no criminal
file was ever initiated against him at the Israeli police, and to the best of his knowledge, no interrogation is currently being
conducted against him.

 

		2.4.	He will keep in confidence all of the terms and details of this Agreement.

 

		2.5.	He is aware that a trial period of three months has been defined (the "Trial Period")
during which the Employee's position will be defined as a Director Business Development and Medical Affairs, during which the Company
shall examine the Employee's suitability for the position of VP Business Development and Medical Affairs and to the Company and
his compliance with his representations and undertakings as specified herein.

 

		3.	The Employee's Undertakings

 

The Employee undertakes the following
towards the Company:

 

		3.1.	The Employee will be employed by the Company in a full time position as shall be required and according
to the instructions of the Company's management, in the position of a VP Business Development and Medical Affairs.

 

		3.2.	To fulfill his Office honestly, devotedly, loyally and skillfully and to do all that is within
his capacity for the promotion of the Company.

 

    	2

    	 

    

 

		3.3.	Subject to the Company's requirements from time to time, the Employee undertakes to dedicate all
of the time and attention required, his qualifications, knowledge and experience for fulfillment of the Office solely for the Company's
benefit and interests.

 

		3.4.	That he will be subject, within his Office, to the Company's CEO, and will comply with his instructions
pertaining to his work and/or position, including, but without derogation, instructions and/or directions regarding work procedures
and any other instruction of the Company's management.

 

		3.5.	That he shall not commit and/or guarantee and/or represent in the name of the Company and will
not impose any liability thereon, and will not use the name thereof, beyond the authorities conferred upon him according to this
Agreement and/or authorities which will be explicitly defined by the Company's management.

 

		3.6.	Not to engage in any other occupation, other than with the Company's advance written consent and
subject to the terms of the consent, if granted.

 

		3.7.	During the term of his employment and within the fulfillment of his Office, the Employee shall
act within the framework of the Company's procedures, discipline rules, articles of association and arrangements, as shall be determined
by the Company from time to time.

 

		3.8.	The Employee will not be entitled to receive, in relation to the performance of his Office, any
consideration or benefit, from any entity whatsoever, including customers or suppliers of the Company. Any amount and benefit,
or the equivalent thereof, which the Employee shall receive contrarily to the aforesaid, will belong to the Company and the Employee
undertakes to return them to the Company upon the first request.

 

		3.9.	To notify the Company immediately and with no delay of any issue in respect of which he has a personal
interest and/or which may create a conflict of interests with the Office.

 

		4.	The salary and benefits

 

		4.1.	During the Trial Period, the Employee will be entitled to a monthly salary of NIS 36,000 gross.
After the end of the Trial Period, his salary will be increased so that in consideration for fulfillment of his Office according
to this Agreement during the period which shall follow the end of the Trial Period, the Employee will be entitled to a monthly
salary of NIS 38,000 gross (the "Monthly Salary").

 

		4.2.	The Monthly Salary will include all of the cost of living adjustments and salary increases paid
to employees in Israel, until and including the date of execution of this Agreement. The Monthly Salary shall be increased from
time to time by the amount of the new cost of living adjustments or the new salary increases which shall be paid to all of the
employees in Israel after the date of execution of this Agreement by virtue of expansion orders of general collective bargaining
agreements regarding cost of living adjustments or salary increases.

 

    	3

    	 

    

 

		4.3.	The Monthly Salary shall be paid to the Employee after any amounts which the Company is obligated
and/or entitled to deduct according to any law and/or this Agreement, no later than the 10th day of the calendar month
following the month for which the salary is paid.

 

		4.4.	The Employee shall be entitled to an annual leave which will be calculated according to a tenure
of 4 years and will be updated according to the Annual Leave Law, 5711-1951, sick pay, recuperation pay and severance pay, according
and subject to the provisions of any law.

 

		4.5.	For avoidance of doubt, it shall be clarified that the Employee's days of leave may not be accumulated
and will be used on days agreed upon between him and the Company. Their redemption, if permitted by law, will be permitted only
after the Employee's termination of work.

 

		4.6.	It is agreed that the Company shall be entitled to deduct from the salary and/or from any payment
which the Employee shall be able to receive from the Company, if any, according to law and/or according to the provisions of this
Agreement, any amount which the Employee shall owe the Company according to the agreements made and/or that shall be made between
them in writing and/or orally and/or which the Company shall be entitled to deduct according to the Employee's instructions and/or
the provisions of this Agreement.

 

		4.7.	The provisions of this Section above constitute an instruction and undertaking according to the
Salary Protection Law, 5718-1958 as well.

 

		4.8.	The Employee hereby represents that he knows and agrees that within the capacity of his position,
which requires a special level of personal trust, he is not included in the employees to whom the Work and Rest Hours Law, 5711-1951
applies, and he will not be entitled to claim or receive any payments or additions due to his working overtime. Alternatively it
is agreed that the salary also includes payment for working overtime, as mandated by the Office.

 

		5.	Managers' Insurance, Study Fund, Other Benefits

 

		5.1.	During the period of application of this Agreement, and subject to directives which will be set
forth from time to time by the Income Tax Commission and according to the permitted ceiling for deduction, the Company will contribute
to the Employee's credit, the contributions according to Section 14 of the Severance Pay Law, 5723-1963, and the Approval of the
Minister of Labor and Social Affairs in an order dated June 30, 1998, which was given according to Section 14 as aforesaid, including
all amendments thereto, and which is attached to this Agreement as Annex A, to management insurance or to a pension
fund.

 

    	4

    	 

    

 

		5.2.	The Company undertakes, commencing from the date of execution of this Agreement, to contribute
an amount in NIS which is equal to 7.5% of the Monthly Salary to a study fund, which will be paid directly to a study fund. The
Employee will deduct an additional amount which is equal to 2.5% of the Monthly Salary as aforesaid. The Employee hereby agrees
that the Company will deduct the said amount from his salary.

 

		5.3.	It is hereby agreed that upon termination of employment according to this Agreement, the Company
will release to the Employee all of the amounts accrued in his name in the insurance policy and which were contributed from his
Salary. In addition, subject to the Employee's compliance with the provisions of this Agreement, the Company shall release to the
Employee also all of the amounts which were accrued in an insurance policy and which were contributed by the Company. The contributions
on account of severance pay will be released according to the Employee's entitlement or absence thereof to severance pay according
to law or according to this Agreement.

 

		5.4.	For avoidance of doubt, in case that the Employee shall be dismissed under circumstances as defined
in Section 16 and/or Section 17 of the Severance Pay Law and/or in case that the work relation between the Employee and the Company
shall be terminated under circumstances of a severe discipline violation, breach of employment contract, betrayal of trust, an
infamous crime as well as upon the occurrence of the events specified in Section 7.5 below, he will not be entitled to severance
pay and advance notice.

 

		5.5.	It is hereby agreed, unequivocally that the amounts accrued in the insurance policy on account
of the Company's participation (i.e. 8.33% of any payment of a gross Monthly Salary) will be in lieu and as a final and
full substitution to any severance pay which the Employee will be or will become entitled to according to any law which shall apply.
This Section is according to Section 14 of the Severance Pay Law, 5723-1963, and the Approval of the Minister of Labor and Social
Affairs in an order dated June 30, 1998, which was given according to Section 14 as aforesaid, including the amendments thereto,
and which is attached to this Agreement as Annex A.

 

		5.6.	It is agreed that the provisions of Sections 4 and 5 above exhausts all of the Employee's entitlements
from the Company for fulfilling his Office as provided in this Agreement and the Employee will have no claim against the Company
and/or any demand in addition to that.

 

    	5

    	 

    

 

		6.	Car and Cellular Phone

 

		6.1.	The Company shall provide the Employee with a private Grade 2 car and will bear all of the expenses
involved in the use of the car (licensing, insurance, repairs and so forth) (the "Car"). Replacing the Car with
a new one shall be done according to the Company's discretion. The tax in respect of the use value which shall apply will be deducted
from the Employee's Monthly Salary according to law.

 

		6.2.	The Employee will ensure proper maintenance of the Car and will use the Car reasonably and with
care. The use and servicing of the Car will be according to the instructions and procedures of the Company as shall be in effect
from time to time.

 

		6.3.	The Employee represents that it has been made clear to him that he is personally responsible for
the payment of the deductable amount in case of an accident and/or stealing the car and is also responsible for the payment of
any traffic fines and/or parking tickets and/or other fines and reports, which will be imposed in respect of the Car in the name
of the Company or in the name of the Employee, all as shall be determined from time to time by the Company. If an employee does
not act as specified in this Section, the Company shall endorse the reports and/or fines as aforesaid in the name Employee's name.
For avoidance of doubt it shall be clarified, that the Employee's liability according to the provisions of this Section will apply
also if the fact of the fines and/or reports in respect of the Car will become known to the Company after the Employee had left
the Company, and that if the Employee will not act as specified in this Section, the Company will endorse the fines and/or reports
as aforesaid, to the name of the Employee.

 

		6.4.	Should the Employee not pay the deductable amount and/or the fines as aforesaid, the Company will
be entitled to pay the amount of the deductable and/or the amounts of the fines and the Employee hereby gives the Company an irrevocable
instruction to deduct such amounts from any amount which he will be entitled to from the Company.

 

		6.5.	The Company shall provide the Employee, for the purpose of fulfilling his Office, a cellular phone.
The Employee will be entitled to use the cellular phone for the purposes of the work and within his Office. The Company shall bear
all of the fixed and current expenses incurred in respect of the cellular phone, up to an amount of NIS 300 per month. Tax in respect
of the use value which will apply shall be deducted from the Employee's Monthly Salary according to law.

 

		7.	The Agreement Term

 

		7.1.	This Agreement is for an unlimited period which will begin on December 15, 2013 (the "Agreement
Term") and subject to the following.

 

    	6

    	 

    

 

		7.2.	As aforesaid in this Agreement and without derogating from the provisions of Section 7.1 above,
the period commencing on the Agreement commencement date and ending three months thereafter, will be the Trial Period. During the
Trial Period, the Company shall examine the suitability of the Employee for the position and his compliance with his representations
and commitments as specified in this Agreement.

 

		7.3.	Cancelled.

 

		7.4.	After the Trial Period, each party will be entitled to terminate the Agreement by an advance notice
according to law.

 

		7.5.	During the entire Agreement Term, the Company shall be entitled to terminate the Agreement immediately,
with no advance notice, upon the occurrence of one or more of the following events:

 

		7.5.1.	If the Employee shall be convicted in a criminal offence, except for a technical offence or one
of strict liability, or if an indictment shall be filed against him in a criminal offence which is a felony or criminal act.

 

		7.5.2.	If the Employee breached his fiduciary duty towards the Company and/or will not act and/or operate
with loyalty and/or credibly and/or honestly towards the Company and/or therefor.

 

		7.5.3.	The Company found out that the Employee's representations in Section 2 of this Agreement and/or
his undertakings, as specified in Section 3 above are untrue and/or incorrect and/or are invalid;

 

		7.5.4.	The Company found out that he Employee had breached any of the provisions of Sections 8-9 below;

 

		7.5.5.	The Employee breached the Agreement and did not correct the breach, even though he had received
a 30 day notice or a shorter notice, according to the urgency of the matter and/or committed a severe disciplinary offence in circumstances
which entitle the employer to dismissal without severance pay.

 

		7.6.	For avoidance of doubt it is agreed, that in each of the cases specified in paragraph 7.5 above,
the dismissal shall enter effect immediately, without requiring the provision of advance notice or payment in respect thereof.

 

		7.7.	Upon the termination of the Employee's work at the Company for any reason, the Employee shall transfer
his Office in a full and orderly fashion to any person that the Company shall instruct him, and will deliver to the Company all
of the documents, information, equipment and material which he received as the Company's employee or that had been prepared by
him in respect to his work at the Company.

 

    	7

    	 

    

 

		8.	Confidentiality

 

		8.1.	The Employee hereby undertakes to keep in confidence and not to disclose, show, deliver, whether
during his employment term or thereafter, with no limitation on time, to any person or body, in Israel or worldwide, trade, professional,
business and other secrets of the Company, or knowledge and/or information pertaining to the Company or related directly or indirectly
to the Company, its property, business and interests, its customers, suppliers, the persons or entities who were or are in contact
with the Company, including, but without derogating from the generality of the aforesaid – creation, concept, invention,
copyright, patent, fabrication, design and any intellectual property right, improvement, idea, process, knowledge, conclusions,
human resources management and salary determination, terms of agreements in which the Company is engaged, and documents of the
Company – all whether the said secrets and/or knowledge and/or information reached him directly or indirectly, within his
work and/or during his work and/or in the process of his work and/or as a result of his employment and/or due to his Office and
whether they reached him directly or indirectly, in any other manner whatsoever. The Employee hereby confirms that the secrets
and/or knowledge and/or information as aforesaid are the Company's exclusive property and that he has no and will have no claims
of any type whatsoever in respect thereto or deriving therefrom.

 

		8.2.	The Employee hereby undertakes not to make use of any kind, in Israel and worldwide, of the secrets
and/or knowledge and/or information specified in Section 8.1 above, except if – and only to the extent such is necessary
– for the purpose of performing his office at the Company. The Employee undertakes thereby not to utilize the said secrets
and/or knowledge and/or information in Israel and/or abroad, for his purposes that are personal and/or for his work in another
workplace, without limitation of time and place.

 

		9.	Intellectual Property

 

Without derogating from the undertaking
annex attached to this Agreement, any confidential information, including a creation, concept, invention, improvement, idea, process,
knowledge, conclusions, copyright, patent, fabrication, perfection, design, development and any other intellectual property right
and so forth – which had been developed or invented by the Employee, alone or in cooperation with others, while or during
or in relation to his work at the Company, will be the Company's exclusive property, and the Employee will have no right of ownership
and/or royalties and/or consideration and/or any other right in respect of such information. Any implementation, analysis, commercialization,
marketing, sale and/or any other use of such analysis and/or invention, will be according to the Company's sole and absolute discretion.
It shall be clarified that the consideration paid to the Employee according to this Agreement includes also consideration for possible
inventions which had been developed or invented by the Employee, alone or in cooperation with others, within or during or following
or in respect of his work at the Company and the Employee will not be entitled to any additional or separate consideration in case
of an invention which he had reached.

 

    	8

    	 

    

 

The Employee will be estopped and
barred from making claims against the provisions of this Section 9 above, both claims resulting from the Israeli law and claims
resulting from any foreign law, and will be prevented from approaching any foreign tribunal and/or judicial and/or administrative
instance. It is agreed that any dispute between the Employee and the Company in respect of the provisions of this Section 9 above,
including claims resulting from any foreign law, will be decided exclusively by the competent courts at the Central District of
Israel and only by them. Any dispute between the Employee and the Company will be subject only to the Israeli law.

 

The provisions of this Section will
apply also after the end of the term of this Agreement, for any reason, or following the expiration of this Agreement, all with
no limitation on time and place.

 

		10.	Remedies in case of breach of the Confidentiality and Intellectual Property Provisions

 

		10.1.	The Employee agrees that the breach of the provisions of Sections 8 and/or 9 above will be deemed
as a fundamental breach of this Agreement and will deny the Employee of his right to payments from the Company, including: severance
pay; advance notice payment as well as other social benefits, all subject to the provisions of any law.

 

		10.2.	The Employee knows and understands that upon the breach of Sections 8 and/or 9 above by the Employee,
the Company shall petition to the court for an injunctive relief against the Employee and/or anyone on his behalf and/or against
any third party related to the Employee's acts and/or omissions, as well as with a monetary tort claim against them in respect
of the damage which will be caused to the Company, without derogating from any other remedy to which the Company will be entitled
by virtue of this Agreement and/or according to any law.

 

		10.3.	Without derogating from the aforesaid, the Employee irrevocably and conclusively waives any right
to the remedy of an injunction and/or mandatory injunction against the employer and any claim and/or demand of the Employee will
be solely for monetary remedy.

 

		11.	Exclusivity and Non Competition

 

The Employee undertakes not to engage,
work, participate and/or consult, directly or indirectly, whether himself or through others, whether as a hired employee, independent
or freelancer, or in any other manner, in a business, position, work or any other occupation which competes and/or might compete
with the Company's business, both during the Employment Term as defined above and during a period of additional 12 months from
the date of termination of the employment term for any reason whatsoever.

 

    	9

    	 

    

 

		12.	Miscellaneous

 

		12.1.	It is agreed that the provisions of this Agreement exhaust the agreements between the parties,
and any promise, undertaking, consent, memorandum of understanding, representation made between the parties, if made prior to the
execution thereof, whether in writing or orally, are hereby null and void, and have no evidential use against the Company.

 

		12.2.	Any change in the terms and provisions of this Agreement requires another written document which
will be executed by the parties to this Agreement.

 

		12.3.	The parties agree that the sole and exclusive jurisdiction, in all matters related to the rights
deriving from and/or related to this Agreement, will be of the competent courts in the Central District.

 

		12.4.	In case that it shall be decided that any provision or provisions of this Agreement is/are unenforceable
or have no effect whatsoever, such will not affect or prejudice the legality, validity and enforceability of the remaining provisions
of the Agreement which are not related to or deriving from the invalid charge.

 

		12.5.	Any delay in the enforcement proceedings of any right according to this Agreement and according
to any law will not be deemed as a waiver of such right or any other right and will not prevent the possibility of claiming remedies
due to the breach of the right, including the enforcement thereof at a later date.

 

		12.6.	The parties undertake to fulfill all of their undertakings in this Agreement with loyalty, in good
faith and based on trust relations.

 

		12.7.	The parties' addresses are as specified in the preamble to this Agreement. Any notice provided
by one party to the other, will be deemed as having been received within 3 business days from the date of delivery thereof by registered
mail, or upon its delivery by a messenger, whichever is earlier.

 

		13.	After the Trial Period

 

Subject to and without derogating
from the provisions of Section 2.5 above, upon the successful completion of the Trial Period and subject to the approval of the
Company's board of directors, the Employee's office definition will be changed to VP Business Development and Medical Affairs who
reports directly to the CEO. In addition and subject to the board approval, options will be granted in accordance with the Company's
compensation policy. Subject to the continued employment of the Employee after the Trial Period, the remaining engagement terms
with the Employee will remain unchanged.

 

In Witness whereto the parties have hereto
set their hands:

 

	/s/ Zeev
    Weiss and Nir Sassi	 	/s/ Liat
Flaishon
	The Company	 	The Employee

 

    	10

    	 

    

 

Annex A 

 

General Approval (Combined Version) Regarding
Employers’ Contributions to 

Pension Funds and Insurance
Funds in lieu of Severance Pay

Under the Severance Pay Law, 5723-1963

[Updated as of February 28, 2001]

 

By virtue of my power under Section 14 of the
Severance Pay Law, 5723-19631 (the “Law”), I hereby confirm, that contributions made by an employer for
his employee, commencing as of the date of publication of this approval, to a comprehensive pension in a provident fund for annuity
that is not an insurance fund within the meaning of such term in the Income Tax Regulations (Rules for the Approval and Management
of Provident Funds), 5724-19642 (a “Pension Fund”) or to a managers’ insurance that includes the possibility
of an annuity or a combination of payments to an annuity plan and to a non-annuity plan within such insurance fund (an “Insurance
Fund), including combined contributions made by the employer to a Pension Fund and to an Insurance Fund, whether or not the Insurance
Fund includes an annuity plan (the “Employer's Contributions”), shall be payable in lieu of severance pay due to such
employee in respect of the salary from which such contributions were made and the period they were made for (the “Exempt
Salary”); provided, however, that all of the following conditions have been fulfilled:

 

		(1)	The Employer's Contributions -

 

		(a)	To the Pension Fund, are at a rate of no less than 14 1/3% of the Exempt Salary, or 12% of the
Exempt Salary, if in addition thereto, the employer makes supplementary severance pay contributions for his employee to a provident
fund for severance pay or to an Insurance Fund in the employee's name, at a rate of 2 1/3% of the Exempt Salary. In the event that
the employer has not contributed such 2 1/3% in addition to said 12%, his contributions shall only replace 72% of the employee's
severance pay;

 

		(b)	To the Insurance Fund are at a rate of no less than one
of the following:

 

		(1)	13 1/3% of the Exempt Salary, if in addition thereto, the employer makes contributions for his
employee for securing monthly income in the event of disability to a plan approved by the Commissioner of the Capital Market, Insurance
and Savings at the Ministry of Finance, at the rate required to secure at least 75% of the Exempt Salary or a rate of 2 1/2% of
the Exempt Salary, whichever is lower (“Disability Insurance Contributions”); or

 

 

		1	Statues 5723, p. 136.

		2	Regulations 5724, p. 1302.

 

    	11

    	 

    

 

		(2)	11% of the Exempt Salary, if the employer also made Disability Insurance Contributions, and in
such case the Employer's Contributions shall only replace 72% of the Employee's severance pay; In the event that the employer has
made, in addition to the foregoing, supplementary severance pay contributions to a provident fund for severance pay or to an Insurance
Fund in the employee's name at a rate of 2 1/3% of the Exempt Salary, the Employer's Contributions shall replace 100% of the employee's
severance pay.

 

		(2)	By no later than three months of the commencement date of the Employer's Contributions, a written
agreement is executed between the employer and the employee that includes:

 

		(a)	The employee’s consent to the arrangement pursuant to this approval in a form specifying
the Employer's Contributions, and the Pension Fund and Insurance Fund, as applicable; such agreement shall also include the form
of this approval;

 

		(b)3	The employer’s advance waiver of any right he may
have to a refund of monies from his contributions, unless the employee’s right to severance pay has been revoked by virtue
of Sections 16 or 17 of the Law, and to the extent so revoked, or the employee has withdrawn monies from the Pension Fund or Insurance
Fund other than by reason of an Entitling Event; in such regard "Entitling Event" means death, disability or retirement
at or after the age of 60 or more

 

		(c)	This approval shall not derogate from the employee's right to severance pay under any law, collective
agreement, expansion order or employment contract, in respect of salary over and above the Exempt Salary.

 

	 	Eliyahu Yishai
	 	 
	 	Minister of Labor and Social Affairs

 

Signature of employee:

 

	 	[Signature]	 
	 	 	 
	Date: November 25, 2013	Signature:	/s/ Liat Flaishon	 

 

 

		3	Amendment: Official Gazette 4803, 5760 (September 19,
1999).

 

    	12

    	 

    

 

Annex B

 

Letter of Undertaking for confidentiality/non
competition/endorsement of intellectual property rights

 

Made and executed on November 25, 2013

 

Between Liat Flaishon I.D. 02226959-1
(the "Employee")

 

and Intec Pharma Ltd. Company Number 513022780
from Jerusalem, 12 Hartom st. (the "Company")

 

		1.	Confidentiality

 

Without derogating from the definition
of "Confidential Information" in the employment agreement to which this Letter of Undertaking for Confidentiality/Non
Competition/Endorsement of Intellectual Property Rights ("This Agreement") is an annex (the "Employment
Agreement"), "Confidential Information" includes research and development pertaining to existing or future
products, inventions, hardware, computer software, databases, chart, technique, drawing, idea, process, manufacturing method, formula,
procedure, business plan, clients, financial information, marketing plans and any trade secret (whether patentable or not), improvements
and knowledge pertaining to the aforesaid, and any information or data related or pertaining to the technology, products or services
of the Company or of companies affiliated thereto (existing, potential or future), or pertaining to the business of the Company
or of companies affiliated thereto (existing, potential or future) in any other manner, including any business information pertaining
to clients and suppliers, whether tangible or not, and any other trade secret, as defined in the Law of Commercial Torts, 5759-1999,
of the Company or of a company affiliated thereto. The aforesaid will not apply to information which had been made public domain
by the Company or in any other legal manner.

 

		1.1.	The Employee shall maintain the confidentiality and secrecy of any Confidential Information as
defined above, which had reached the Employee's knowledge during the provision of the services or the engagement with the Company
or an affiliated company thereof or as a result therefrom, and the Employee will not disclose, use, publish or otherwise expose,
directly or indirectly, Confidential Information as aforesaid at any time during or after the expiration of the term of his employment
by the Company, with no limitation of time and place, without the explicit approval of a competent representative of the Company
in advance and in writing.

 

		1.2.	Any Confidential Information, whether it is in written material, documents, computer software and/or
hardware, electronic media, magnetic media, servers or in any other form or manner (all hereinafter: the "Documents")
including notebooks, notes, memos, records, diagrams, drawings, bulletins, formulas, reports, computer programs, other information
of any type whatsoever which reached the Employee's possession or which was prepared by the Employee or by others, is the Company's
or an affiliated company's exclusive property, as the case may be. The Employee hereby undertakes to return to the Company Documents
as aforesaid or any other material which belongs to the Company that is in his possession (a) if he was requested to do so by the
Company or (b) upon the termination of the Employee's employment by the Company, whichever is earlier, and if he was requested
to do so by the Company, to sign a written statement in which he will confirm that he has carried out the aforesaid.

 

    	13

    	 

    

 

		1.3.	It is clear and understood by the Employee that all of the confidential information is material
business information which is the property of the Company or of companies affiliated thereto, or of third parties to whom the Company
or the affiliated companies thereto have a duty of confidentially, which is not public domain and which may not easily be discovered
by others, whose confidentiality provides the Company or affiliated companies thereof, a commercial advantage over their competitors,
and that the Company takes reasonable measures to maintain the confidentiality thereof.

 

		1.4.	The Employee's undertakings according to this Agreement are towards the Company and any parent
company, subsidiaries, affiliated companies and anyone which shall replace it according to law, as in effect from time to time.

 

		1.5.	The Employee's undertakings pursuant to this Section, will remain in effect after termination of
the Employee's employment, according to the Employment Agreement.

 

		2.	Non Competition

 

		2.1.	The Employee agrees that during the term of the Employment Agreement and for twelve months following
termination thereof, for any reason whatsoever, he will not engage, be involved or affiliated in any manner, or employed, directly
or indirectly, alone or together with others, for himself or as an agent, broker, manager, licensor, employee, officer, director,
partner, member of a joint venture, shareholder, investor, consultant or otherwise, and without the Company's prior written notice,
in any business or venture, anywhere in the world, which engages in any activity within which (a) there are products or services
which compete with products or services of the Company, or with products or services of the Company's affiliated companies pertaining
to the Company's business, as they were upon the termination of the Employees' employment (b) there are information, processes,
technology or equipment in which the Company has a proprietary right, or in which a company affiliated to the Company has a proprietary
right, and which are related to the Company's business which exist currently or will exist in the future, or which are based on
technology similar to that which was developed by the Company. The aforesaid will not apply to (a) holding securities in any company
whose shares are traded in public on the stock exchange which received international acknowledgement, provided that such holding
will not exceed 1% of the issued share capital of a public company as aforesaid, and the Employee does not fulfill an active office
in a public company as aforesaid as a director, employee, consultant (including independent consultant) or any other active position,
or (b) non-commercial activities which constitute de minimis.

 

    	14

    	 

    

 

		2.2.	The Employee agrees, that for the period of the Employee's employment by the Company and for a
period of 24 months from the date of termination of his employment, for any reason whatsoever, the Employee will not solicit or
encourage, directly or indirectly, himself or within a business in which the Employee is an employee, officer, director, shareholder,
consultant or contractor, for any purpose and at any place, a person who was employed by the Company or an affiliated company thereof,
to terminate their employment with the Company or a company affiliated thereto, as the case may be.

 

		2.3.	The Employee agrees that for two years from the date of termination of engagement in the Employment
Agreement, he will not employ, directly or indirectly, a person who was employed by the Company or a company affiliated thereto,
during the two years which preceded the engagement termination date, as aforesaid.

 

		3.	Endorsement of Intellectual Property Rights

 

		3.1.	For the purposes of this Annex, the following definitions shall apply:

 

"Inventions" mean,
inter alia, any invention, discovery, idea, improvement, change, betterment, document, software, hardware, firmware, creation,
form, mask works, work, chart, original creation, formulas, techniques, methods, systems, processes, compositions of material,
databases, knowledge, information and trade secrets, which were created, invented, discovered, developed, composed or processed
by the Employee during his employment or twelve (12) months thereafter (or the maximal period permitted by law if its shorter),
in whole or in part, or that the Employee's efforts contributed to the creation thereof, independently or in cooperation with others,
whether patentable or protectable by virtue of copyrights or another protection or not, and:

 

		(a)	Which are related, directly or indirectly to the Company's business, as defined in the Employment
Agreement, including a platform for gastric drug retention or which were created while using the Company's equipment; or

 

		(b)	Which are related to existing research and development or in respect of which it can be proven
that they are being planned, pertaining to the Company's business, or research and development as aforesaid of the Company's affiliated
company; or

 

		(c)	Which are developed, in whole or in part, during the Company's working hours, or by using equipment,
supply, facilities or confidential information of the Company or of a company affiliated thereto.

 

    	15

    	 

    

 

"Trade Secrets" mean
"trade secrets" as defined in the Law of Commercial Torts, 5759-1999, and any record, software, hardware, form, client
list, knowledge and information of any type or nature, pertaining to the Company's business, in the past, present or future, or
any plans in respect thereof, or pertaining to the business of a third party, in the past, present or future, or to any plans in
respect thereof (including any object or information in any form whatsoever in respect of which it had been provided in law that
is a trade secret) which reached the Employee's knowledge, which the Company does not disclose to third parties with no restrictions
on use or restrictions on the disclosure to other third parties.

 

		3.2.	Without derogating from any other provision of law:

 

		a.	The Employee will put into writing, and will expose before the Company or a company affiliated
thereto, together with explanations, any invention and will conduct accurate records regarding the contemplation of any invention
and implementation of the idea. Such records will be the Company's exclusive property, and the Employee will deliver possession
in the records to the Company, upon the termination of his engagement with the Company.

 

		b.	The Employee hereby assigns to the Company or to the affiliated companies thereof, with no additional
consideration to the Employee, the full and exclusive rights, ownership, possession and title in the Inventions, and in all of
the proprietary and intellectual property rights therein, and in the proprietary and intellectual property rights deriving therefrom
or based thereon, both in Israel and abroad. The Employee will sign any assignment, statement or other document which will be prepared
by the Company for giving effect to the aforesaid. The Employee hereby confirms and will confirm in the future the exclusive intellectual
property rights of the Company and of affiliated companies thereof, in Israel and abroad, in all of the Inventions.

 

		c.	During the Employment Agreement term and thereafter, the Employee shall provide the Company with
any reasonable information, document and assistance which the Company shall require in order to prepare, perform and complete the
registration of the proprietary rights, intellectual property and his patent in the Inventions and the trade secrets and the rights
as aforesaid deriving from the invention and in the trade secrets or which are based thereon, to protect them or enforce them,
in any jurisdiction according to the Company's discretion. The Company, according to its sole discretion, will determine the scope
of the rights as aforesaid in the inventions and trade secrets or deriving therefrom, if there shall be such, which must be protected.
Such assistance includes the preparation of documents, drawings and other data, and the signing of right assignment documents,
applications and other forms. Any such information, document and assistance will be provided to the Company by the Employee with
no additional cost for the Company, except for out-of-pocket cash expenses actually incurred by the Employee upon the Company's
request.

 

    	16

    	 

    

 

		d.	During the Employment Agreement term and thereafter, the Employee will maintain the secrecy and
confidentiality of the Inventions as if they were Confidential Information pursuant to this Agreement, will not expose them to
others without obtaining prior written permission from the Company and will not use such Inventions for any purpose whatsoever,
except for the purpose of performance of services for the Company.

 

		4.	Remedies

 

It is clear to and understood by the Employee
that the breach of the undertakings included in this Agreement or any part thereof, shall cause the Company or affiliated companies
thereof severe and irreversible damage. In view of the aforesaid, the Employee agrees that in case of such breach or anticipated
breach, the Company, the Company's affiliated company or anyone to whom the Company or an affiliated company thereof had assigned
their rights to, will be entitled, without prejudice to any rights, and in addition to other rights, remedies and compensation
available thereto by law or equity, to a preliminary or perpetual injunction, or any other possible equitable remedy, in order
to prevent or remove the breach or the attempted breach of this Agreement by the Employee or by any person or entity acting for
him or on his behalf. In case that proceedings had been initiated for enforcement of the terms of the restrictions in the Agreement
as aforesaid, the lawfully winning party will be entitled, in addition to any other remedy, to the restitution of any reasonable
amount in respect of legal fees and other expenses which were involved in the measures initiated, both in the trial court and in
the court of appeals, and in any bankruptcy proceeding. In case that a competent court shall decide in a final decision that is
no longer appealable, that the scope, duration of time or geographic boundaries specifically determined in any of the restrictions
set forth in the Agreement are too extensive for enforceability, the said court will be authorized, and the parties to this Agreement
agree and determine hereby, that such court will amend the terms of the restrictions as aforesaid and will enforce the terms according
to the scope, duration of time and geographic boundaries which it will deem just and appropriate, while taking the parties' intention
into account.

 

		5.	Confirmations and Representations

 

The Employee hereby represents
and confirms the following:

 

		5.1.	The Employee's undertakings for non competition and confidentiality according to this Agreement
are fair, reasonable and proportionate and were intended to protect secrets and confidential information of the Company and affiliated
companies thereof, which are the essence of the Company's protectable business and commercial advantages in which significant capital
has been invested.

 

    	17

    	 

    

 

		5.2.	Breach of his aforesaid undertakings – will be contrary to the special fiduciary and loyalty
relations between the parties as employee and employer, to proper commerce practices, and to the duty of good faith and fairness
between the parties, it will prejudice the Company's business, and will constitute a fundamental breach of This Agreement and of
the Employment Agreement.

 

		5.3.	It is clear to and understood by the Employee, that the limited time period and the geographic
area as specified in this Agreement are reasonable in view of the nature of the Company's business and the knowledge of the Employee
pertaining to the Company's business.

 

		5.4.	The Employee represents that his undertakings pursuant to this Section, which are reasonable and
proportionate – do not prevent him from developing the general knowledge and professional expertise in the field of his occupation,
in respect to parties who are not customers or employees of the Company, and without stealing the Company's secrets.

 

		5.5.	The Company will be entitled to assign the undertakings of the Employee thereto in this Agreement.
The Employee will not be entitled to assign or to transfer to another his duties pursuant to this Agreement without the Company's
prior written approval. This Agreement binds the Employee's heirs, permitted assignees and anyone who shall come in his lieu according
to law.

 

	/s/ Liat Flaishon	 	/s/ Zeev Weiss and Nir Sassi
	The Employee	 	Intec Pharma Ltd.

 

 

    	18

    	 

    

 

Annex C

 

Procedure for prohibition of
abuse of inside information

 

Preamble

 

This procedure is designated for
officers at Intec Pharma Ltd. (the "Company"), including directors, CEO, VP's and other senior officers directly
subject to the CEO as well as for the Company's employees.

 

Prohibited use of Inside Information
exposes both the user and the Company to civil and criminal sanctions and is liable to cause the Company significant financial
and reputational damage. Therefore, this procedure is designated to clarify what is permitted and prohibited in this field and
to present the "do's" and "don'ts".

 

Basic Terms

 

Inside Information definition

 

The Securities Law, 5728-1968 (the
"Law") sets forth a prohibition of the use of Inside Information in a company whose securities have been offered
to the public pursuant to a prospectus or are traded on the stock exchange and are in the hands of the public, including a subsidiary4
and an affiliated company5 of the same company. Such prohibition is one of the cornerstones of Securities laws and it
is based on the aspiration to create a capital market in which fair and equal competition occurs.

 

Inside Information is defined in
the law as "information about development in the company, a change in its condition, anticipated development or change, or
other information about the company which is not known to the public and which had it become known to the public, it could have
caused significant change in the price of a security of the company or in the price of another security, of which a security of
the company is an underlying asset"6.

 

The aforesaid definition does not
set forth a closed list of types of information which are included therein, and therefore, extensive room for interpretation by
the courts remains in this context. Following is a non exhaustive list of examples for Inside Information:

 

		·	Engagement of the Company in a material transaction. In this matter, the materiality of the transaction
will be examined, inter alia, according to its immediate and/or future financial scope.

 

 

4
Section 1 of the Law determines that a "Subsidiary" is: " accompany in which another company holds fifty
percent or more of the par value of the issued share capital thereof or of the voting power therein or is entitled to appoint half
or more of the managers or the general manager thereof:

5
 Section 1 of the Law determines that an "Affiliated Company" is: "an associated company as well as a company,
in which another company who is not its parent company, invested an amount which is equal to twenty five percent or more of the
equity of the other company, whether in shares or otherwise, except for a loan which is given in the normal course of business".

6
 Section 52A of the Law.

 

    	19

    	 

    

 

		·	Cancellation of a material transaction.

 

		·	Grant or receipt of a merger offer.

 

		·	Purchase or sale of a material asset of the Company.

 

		·	Initiation of legal proceedings with potential material effect on the Company or a decision in
such proceedings.

 

		·	Financial data, financial results, projections or profits in the Company or in a subsidiary or
in an associated company.

 

		·	Retirement or replacement of senior officers at the Company.

 

		·	Decision regarding dividend distribution.

 

		·	Any material decision of the Company's management or board of directors.

 

		·	Other material business information.

 

It shall be emphasized that procedures
pertaining to the issues specified as aforesaid, might be deemed as "Inside Information", for example the existence of
negotiations regarding a material engagement or the purchase of a material asset, financial statements draft, a material resolution
proposal submitted to the Company's board of directors and so forth.

 

Inside Information shall be deemed
as such which had been published to the public only after distributed among the investing public and absorbed thereby. The Law
determines that information is not deemed as Inside Information if the ISA or the stock exchange received a report regarding the
information and the ISA or the stock exchange published it, or it had been otherwise published in the accepted manner for bringing
such information to the public's knowledge, and a trade day at the stock exchange had elapsed, after the publication date as aforesaid;
should the ISA or stock exchange fail to publish the information within four days from the date on which it was reported, the information
shall cease being Inside Information upon the expiration of such period"7.

 

It shall be stated that in the decision
from October 6, 2011, the Securities Authority (the "ISA") decided that in the opinion of the ISA staff "information
is not deemed as information which is unknown to the public (and therefore it is not deemed as "Inside Information")
if 30 trade minutes had elapsed from the date on which the information was released to the public on the distribution system of
the ISA (the Magna)". It was further stated, that during the 30 minutes in which the information is released on the Magna
system, it can be examined by the public and be expressed in the security price on the stock exchange"8.

 

 

7
 Section 52F(a) of the Law.

8
 The ISA's staff position in respect of a preliminary directive application of the Trust Investment Funds Managers Union
(Registered Association) dated October 6, 2011.

 

    	20

    	 

    

 

The ISA further determined in that
decision that the existence of the presumption described above does not deny the possibility to prove the public knowledge in respect
of the information in another manner as well. For example, if a material claim was filed against the Company and the fact of the
filing thereof had been published in the press before the complaint had been served to the Company, and in any case before the
Company had reported to the public regarding the filing of such claim, the Company will be entitled to claim that the information
which was included in the journalistic publication, is public information which does not constitute "Inside Information".

 

The possible effect of the information
on the Company's security price is a forward-looking hypothetic examination. The examination as aforesaid is done on the date of
actual performance of use of the Inside Information and before the Inside Information had been released to the public.

 

Insiders at the Company

 

The Law determines that
an insider in a company is9 -

 

		1.	A Director;

		2.	CEO;

		3.	A shareholder holding10 five percent or more of the par value of the issued share capital
or of the voting power at the Company or who is entitled to appoint one or more directors at the Company (a "Key Shareholder
at the Company");

		4.	Another person whose status or position at the Company or his relations therewith gave him access
to Inside Information on the date which use of Inside Information was done or within the six months which preceded such date;

		5.	A spouse, sibling, parent, parent of a parent, descendant, or descendant of the spouse, or the
spouse of any of these ("Family Member") of any of those listed in Sections 1-4 above;

		6.	A corporation controlled11 by one of those listed in Sections 1-5 above.

 

 

9
 Section 52A of the Law.

10
 Section 52A of the Law stipulates that "holding" is: "whether alone or with others, whether directly or
indirectly, through a trustee, a trust company or a transfer agent or in any other manner; when holding is by a company –
also by a subsidiary by implication, and when holding by an individual, an individual and his family members living with him, or
that the livelihood of one is upon the other, will be deemed as one person:

11
 Section 1 of the Law determines that "control" is: "the ability to direct the activity of a corporation,
except for the ability deriving solely from the fulfillment of a position of director or another position in the corporation, and
a person is presumed as controlling a corporation if he holds half or more of a certain type of the means of control in the corporation".
Section 1 of the Law determines that a "Means of Control" is: "(1) the voting right at a company's general meeting
or an equivalent entity of another corporation; (2) the right to appoint directors of the corporation or his general manager".

 

    	21

    	 

    

 

Use of Inside Information

 

The Law defines as use of Inside Information,
both the direct action pertaining to the performance of a transaction12 in a security of the Company while the maker
of the transaction or the Company are in possession of Inside Information, and the indirect transaction pertaining to the delivery
to another of Inside Information or an opinion on a security of the Company, by anyone who holds Inside Information, while he knows
or there are reasonable grounds to assume that such other will use the Inside Information or the opinion delivered thereto.

 

The Law stipulates in this context a presumption
according to which "should a key insider at a company purchase securities of the company in which he serves as a key insider
or other securities of which the company's securities are an underlying asset, within three months from the date on which he sold
such securities or he sold such securities within three months from the date on which he bought such securities, it shall serve
as prima facie evidence that he had used the Inside Information which is in his possession, unless he shall prove that he
had no Inside Information in his possession at the time of sale or purchase, or that in the circumstances of the matter he probably
had no Inside Information in his possession at the time"13.

 

The Law determines that a key insider in a
company is –

 

		1.	A director, CEO, deputy CEO, VP, comptroller and internal auditor and anyone fulfilling such a
position, even if the title of the position is different as well as an individual who is a key shareholder at the Company;

 

		2.	A Family Member of any of those listed in Section 1 above;

 

		3.	A corporation controlled by one of those listed in Sections 1-2 above.

 

Criminal
Liability 

 

The Law determines that an insider at a company
who uses Inside Information which is in his possession, is liable for five years of imprisonment or a maximal fine of approx. one
million NIS. Within the Improvement of Enforcement Proceedings in the ISA Law, 5771-2011 (the "Improvement of Enforcement
Proceedings Law") a more severe maximal fine was set forth, in respect of a corporation, of approx. five million NIS.

 

The Law determines that anyone who uses Inside
Information which had reached his possession, directly or indirectly from an insider at the Company, is liable for two years of
imprisonment or a maximal fine of approx. NIS 200,000. Within the Improvement of Enforcement Proceedings Law a more severe fine
was set forth, in respect of a corporation, in the amount of approx. one million NIS.

 

 

12
 Section 52A of the Law determines that a "transaction" is: "the sale, purchase or exchange of a security,
signing a security or an undertaking for the performance of each of those, whether the person is acting for his own benefit or
acting to the benefit of another, and even if he acts through an agent or a trustee".

13
 Section 52E of the Law.

 

    	22

    	 

    

 

It shall be stated that the law allows a company
in whose security a transaction was made while using Inside Information, to claim the profit deriving from such transaction from
such person. Namely, the amount of the difference between the price of the security in which the transaction was done and its price
soon after the Inside Information became known to the public14.

 

Also, the use by a person of Inside Information,
could constitute breach of a fiduciary duty or a contractual duty, and in such case, create tortious or contractual liability.

 

Administrative Proceeding

 

The Improvement of Enforcement Proceedings
Law set forth a mechanism of administrative enforcement, which was intended to make the provisions of the Law more efficient, inter
alia. A seventh supplement was added to the Law, in which a list of administrative offences according to their severity is
detailed in three parts, while the intensity of the punishment is adapted to the level of the breach severity. In this framework
it was determined that for breach of the use of Inside Information it will be possible to initiate an administrative proceeding.
Breach of the use of Insider Information was classified as a very severe breach in respect of which it will be possible to impose
on an individual breaching party a maximal monetary sanction of approx. one million NIS and on a breaching party which is a corporation,
a maximal monetary sanction of approx. five million NIS.

 

Defenses

 

The defenses stipulated in the Law15
were designated to release from criminal and civil liability in a case which the performer of the transaction acted with no connection
to the Inside Information or when the Inside Information was not underlying the performance of the transaction. The burden to prove
the defenses as aforesaid lies on the shoulders of the defendant and the level of proof thereof is according to the balance of
probabilities.

 

The aforesaid defenses are divided into defenses
granted to specific entities acting by virtue of the authority given to them within their position or with no connection to the
Inside Information (such as office holders, agents, trustees etc.), defenses granted due to the existence of a legitimate purpose
for the performance of the transaction (such as a transaction which is a good faith performance of an underwriting contract) and
perimeter defense (such as a transaction outside the stock exchange with a person who also had possession of the Inside Information).

 

"Do's" and "Don’ts"

 

General Provisions

 

		·	As a general rule, use of Inside Information will only be done for the purpose for which it was
created or delivered.

 

 

14
 Section 52H of the Law.

15
 Section 52G

 

    	23

    	 

    

 

		·	The delivery of Inside Information must be restricted only to entities in the Company required
thereto for the fulfillment of their position or to the extent such is relevant externally, such as auditors, legal counsels, parties
to the transaction etc. For example, the finance personnel at the Company will not discuss the Company's financial results for
as long as such constitute "Inside Information" with an entity who is not part of the Company's management or the Company's
finance department.

 

		·	To the extent possible, Inside Information delivered or created in writing must be marked with
a sign such as "Sensitive Information", "Confidential – Internal" etc.

 

		·	External entities being exposed within their position to Inside Information of the Company, must
be informed regarding the sensitive nature of such Inside Information. It shall be emphasized that such informing is not required
in case of disclosure to the attorneys and/or auditors of the Company.

 

		·	Third parties with whom the Company engages and who might be exposed to Inside Information, intentionally
or unintentionally, must sign confidentiality agreements which include also specific reference to the prohibition on the use of
Inside Information.

 

		·	Proper data protection measures must be used in order to prevent and/or restrict access to computers
and/or databases of the Company on which Inside Information is stored (mainly, but not only, desktops or laptops which are used
by key insiders at the Company and/or the finance department staff).

 

		·	The provision of "hints", "indications" etc. must be avoided, regarding potential
effect of Inside Information without the provision of such information. General statements such as "very good things are happening
at the Company" or "after we release the financial statements the share will fly", could constitute Inside Information
the use of which is prohibited.

 

		·	In general, it is preferable that the conduct vis-à-vis investors, analysts and capital
market entities, within which Inside Information could be exposed, will only be done by officers who had been appointed therefor
by the Company's CEO.

 

		·	The provision of Inside Information in a selective or arbitrary manner must be avoided.

 

		·	"Inside Information" is not limited strictly to information pertaining to the Company
directly. Information pertaining to other traded companies, such as information regarding an anticipated collapse of the Company's
competing company, could constitute Inside Information the use of which is prohibited.

 

Financial Statements

 

		·	As a general rule, the period from the initial formulation of the Company's quarterly and/or annual
financial statements and until the release thereof, is an especially sensitive period, especially in all matters pertaining to
the concern of using Inside Information.

 

    	24

    	 

    

 

		·	According to the aforesaid, anyone who had been exposed to the Company's draft financial statements,
including his Family Members as defined above, are mandated to avoid the performance of a transaction in the Company's securities
and/or the derivatives thereof, for so long as the financial statements have not been released as aforesaid at the public.

 

		·	For the sake of good order, it is recommended that the employees and Insiders at the Company will
avoid the performance of transactions with the Company's securities during the period from the date of release of its quarterly
financial statements and until the lapse of two business days from the date on which such statements had been released, and within
the period from the date of release of its annual financial statements and until the lapse of three business days from the date
on which such statements had been released.

 

Repurchase of securities

 

		·	As a general rule, and subject to the provisions of law, any company may perform repurchase of
the securities which had been issued thereby, without the approval of a court and subject to the distribution rules.

 

		·	However, repurchase of securities which might, in itself, be carried out for legitimate financial
reasons, is liable sometimes to raise suspicion of violation of the prohibition of use of Inside Information.

 

		·	The law determines that a corporation will not bear liability for a transaction in securities which
was made by the corporation while the corporation or the employee thereof had Inside Information pertaining to the transaction,
if the corporation proved that the employee or director who performed the transaction had no such Inside Information and that there
is a reasonable explanation for the performance of the transaction16.

 

		·	In a position statement dated July 26, 2010, the ISA set forth a safe harbor defense in the repurchase
of securities by a corporation17. Such defense will be available to the Company if several conditions, as stipulated
in the position statement as aforesaid will be fulfilled. In a nutshell it may be said that if the repurchase is being carried
out under a mechanism of "automatic pilot", the safe harbor defense shall be established.

 

In further detail:

 

		o	The Company must form a written repurchase plan which will set forth parameters of quantity, price
and date for performance of the securities purchase;

 

		o	The Company must set forth an irrevocability provision of the plan so that the Company cannot interfere
and amend or withhold or affect the performance of the purchases after adoption of the plan;

 

 

16
 Section 52G(b) of the Law.

17
Legal position number 198-19: Safe Harbor defense in the repurchase of the securities by the corporation dated July 26,
2010.

 

    	25

    	 

    

 

		o	A commencement date for the plan will be set forth, which will be after the lapse of one trade
day from the release date of the first financial statement after adoption of the plan, in order to allow the investing public to
absorb the information contained in the financial statement prior to the commencement of the plan;

 

		o	The repurchase will be carried out through an independent external entity (member of the stock
exchange);

 

		o	A maximal bar for repurchases per day shall be set forth.

 

It shall be clarified that it is possible to
carry out repurchase of securities also without compliance with the safe harbor defense, however in such case, there shall be exposure
of the Company and those acting on its behalf. Also, the safe harbor defense will not apply to the purchases of individuals, including
interested parties and officers of the Company, who purchase securities of the Company for themselves. Namely, insiders in the
Company will not be able to defend against a claim of making a transaction while using Inside Information, based on the claim that
they had directed a member of the stock exchange in advance to buy and sell securities of the Company under certain conditions.

 

I confirm that I have read the aforesaid
procedure and that its meaning is clear to and understood by me.

 

	/s/ Liat Flaishon	 
	Liat Flaishon	 

 

    	26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]